Sugi Predict

Sugi Predict / Compounds / SCHEMBL393133

SCHEMBL393133

SCHEMBL393133

CC(C)(C)OC(=O)NC(CO)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.48
▸ PPARG P37231 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ TRPA1 O75762 1/20 0.45
▸ RIPK1 Q13546 1/20 0.43
▸ P2RY2 P41231 1/20 0.43
▸ CACNA1B Q00975 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ S1PR3 Q99500 2/20 0.42
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ DRD2 P14416 1/20 0.40
▸ CTSL P07711 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14847725 1.00 GAA (0.48) GAAPPARGPPARAALDH1A1MAPT
SCHEMBL17603813 0.89 P2RY2 (0.46) GAAPPARGPPARAALDH1A1MAPT
SCHEMBL390753 0.89 P2RY2 (0.46) GAAPPARGPPARAALDH1A1MAPT
SCHEMBL391157 0.89 P2RY2 (0.46) GAAPPARGPPARAALDH1A1MAPT
SCHEMBL20544831 0.87 PPARG (0.46) GAAPPARGPPARAALDH1A1MAPT
SCHEMBL391128 0.87 PPARG (0.46) GAAPPARGPPARAALDH1A1MAPT
SCHEMBL392217 0.87 PPARG (0.46) GAAPPARGPPARAALDH1A1MAPT
SCHEMBL2011973 0.87 CTSS (0.47) PPARGPPARARIPK1CTSSCTSK
SCHEMBL28995700 0.87 PPARG (0.45) PPARGPPARAALDH1A1RIPK1LMNA
SCHEMBL1553363 0.87 CTSS (0.47) PPARGPPARARIPK1CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704094-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-11 — — EP disclosed
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-10654855-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2020-05-19 — — US disclosed
US-20180312516-A1 Protein Kinase B Inhibitors ASTRAZENECA AB (SE) 2018-11-01 — — US disclosed
US-10059714-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2018-08-28 — — US disclosed
US-9492453-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2016-11-15 — — US disclosed
US-9376425-B2 Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer AMGEN, INC. (US) 2016-06-28 — — US disclosed
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2015-07-02 — — US disclosed
US-20140235629-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. 2014-08-21 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-5610183-A Phenylglycine derivatives pharmaceutical compositions containing them and their use in therapy MERCK, SHARP & DOHME LTD. (GB) 1997-03-11 — — US disclosed
EP-0593615-A1 AROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY. MERCK SHARP & DOHME (GB) 1994-04-27 — — EP disclosed
WO-1993001165-A2 AROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY MERCK SHARP & DOHME LIMITED (GB) 1993-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885
US-20180312516-A1 Protein Kinase B Inhibitors PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885
US-10654855-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885
US-20140235629-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER MDM2, TP53, CDKN1A GAA 908/4885PPARG 2439/4885PPARA 2855/4885
US-10059714-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 GAA 2360/4885PPARG 3172/4885PPARA 3942/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 GAA 2360/4885PPARG 3172/4885PPARA 3942/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 GAA 2360/4885PPARG 3172/4885PPARA 3942/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 GAA 2513/4885PPARG 3405/4885PPARA 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.